Electroporated vaccination with the melanoma antigen, pINGmuTyr, was conducted in a Phase I trial to assess the appropriate dose and response, and they found that measurements of CD8 tumor-infiltrating lymphocytes improved most in the 1.5 mg dosage group [79]. This evidence concerns the gene CD8A and melanoma.